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Antigen-specific immunotherapy of autoimmune and
allergic diseases
Catherine A Sabatos-Peyton*, Johan Verhagen* and David C WraithNearly a century has passed since the first report describing
antigen-specific immunotherapy (antigen-SIT) was published.
Research into the use of antigen-SIT in the treatment of both
allergic and autoimmune disease has increased dramatically
since, although its mechanism of action is only slowly being
unravelled. It is clear though, from recent studies, that success
of antigen-SIT depends on the induction of regulatory T (T reg)
cell subsets that recognise potentially disease-inducing
epitopes. The major challenge remaining for the widespread
use of antigen-SIT is to safely administer high doses of
immunodominant and potentially pathogenic epitopes in a
manner that induces T cell tolerance rather than activation. This
review illustrates that intelligent design of treatment agents and
strategies can lead to the development of safe and effective
antigen-SIT.
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Introduction
Current treatments for allergic and autoimmune disease
treat disease symptoms or depend on non-specific
immune suppression. Treatment would be improved
greatly by targeting the fundamental cause of the disease,
that is the loss of tolerance to an otherwise innocuous
antigen in allergy or self-antigen in autoimmune disease
(AID). Much has been learned about the mechanisms of
peripheral tolerance in recent years. We now appreciate
that antigen presenting cells (APC) may be either immu-
nogenic or tolerogenic, depending on their location,
environmental cues and activation state [1]. Furthermore,
it is clear that both FoxP3+ and FoxP3 cells with
regulatory properties can be induced with specific anti-
gen. This, therefore, provides two guiding principles
for the design of antigen-specific immunotherapeutic
Open access under CC BY license.www.sciencedirect.comstrategies. First, antigen should be directed to tolerogenic
rather than immunogenic APC; secondly, administration
of antigen should lead to the induction of regulatory
T cells.
Allergen-specific immunotherapy
The application of allergen-SIT has become increasingly
popular since first reported by Leonard Noon in 1911.
Subcutaneous (s.c.) or oral/sublingual administration of
allergens has been used for the successful treatment of a
wide range of allergies including those to bee venom [2],
cow’s milk [3], peanut [4] or birch pollen [5]. Typically,
this starts with a build-up day where the maximum
tolerated dose is determined. This dose is then gradually
escalated over a period of approximately two months to a
high maintenance dose, which is administered regularly
for months to years. By escalating the treatment dose, a
maintenance dose can be reached that is far higher than
the maximum tolerated dose at onset, with limited
adverse effects. Studies have shown that optimal results
are achieved using the highest tolerable maintenance
dose [6] or a high cumulative dose, that is long-term
treatment [7]. To further prevent adverse effects and
increase efficacy, a wide range of novel therapeutic strat-
egies have been employed, including the use of non-IgE
binding allergen derivatives, adjuvants, alternative routes
of administration, fusion proteins, allergen-encoding
cDNA and peptides that represent T cell epitopes
(reviewed in [8]). Hypoallergenic peptides, in particular,
are an increasingly popular alternative to whole proteins
and have proven successful in animal models and human
trials [9,10,11].
Progress in the development of allergen-SIT has been
hindered by a lack of understanding of the underlying
immunological mechanisms. In recent years, it has
become clear that the ratio of allergen-specific T cells
secreting distinct cytokines plays a crucial role in the
onset and cessation of allergic diseases. First, it is import-
ant to realise that allergic and non-allergic individuals
recognise the same T cell epitopes of common allergens
[12] and that only the frequency of different subsets of
CD4+ T cells specific for these epitopes differs. It is now
clear that the balance between effector T cell populations
on the one hand and IL-10-secreting, suppressive T cells
on the other makes the difference between an atopic or
healthy immune response. In atopic individuals, the high-
est proportion of T cells recognising common environ-
mental allergens are IL-4-secreting T helper (Th) 2
cells, whereas IL-10-secreting T cells prevail in healthyCurrent Opinion in Immunology 2010, 22:609–615
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Table 1
Studies demonstrating the importance of IL-10 induction for successful allergen-SIT.
Allergen Treatment Patients Outcome Ref.
Peanut Titrated oral administration of peanut
protein up to 1800 mg (total 36 months)
29 Reduction in IgE; increased IgG4;
increase in IL-10, IL-5, IFN-g and TNF-a. Increase
in antigen-specific FoxP3+ cells until 12 months
[4]
Birch pollen Incremental weekly doses of s.c. standard
quality birch pollen allergen up to 100,000 units,
followed by monthly maintenance dose
13 Increase in antigen-specific IL-10-secreting cells;
increase in allergen-specific IgG antibodies
[5]
Fel d 1 (cat) Asthma patients received intradermal (i.d.)
fel d 1 peptides in increments up to a 90 mg
total over two weeks
16 Reduced late reaction to cat dander;
increased IL-10, with linked epitope suppression
[11,15]
Japanese cedar
pollen
Sublingual application of a pool of
7 Cry j 1 and 2 derived peptides
75 Increase in IL-10-secreting regulatory cells;
reduction in allergy symptoms to cedar
pollen and other allergens
[16,17]individuals [13]. The importance of the dominance of the
IL-10-secreting T cell population for a healthy immune
response to allergens is elegantly demonstrated in the
case of beekeepers [14]. During the season, beekeepers
are stung frequently, thus receiving repetitive high doses
of allergen. Remarkably, their immune response to the
venom skews rapidly, with a dramatic shift in the domi-
nant T cell subtype towards IL-10-secreting cells. This
induction of IL-10-secreting cells has now also been
shown to be a dominant feature of successful allergen-
SIT in a range of allergies (Table 1) [4,5,11,15,16].
Allergen-SIT is successful at any age but early treatment
of a single allergy may prevent epitope spreading and
hence limit the atopic march in later life [17].
Autoantigen-specific immunotherapy
The use of SIT for AID has lagged behind SIT for allergy.
This may be because AIDs are more heterogeneous than
allergic diseases; the disease-initiating or target antigen
may not be known; and/or the immune pathogenesis of
AID is associated with epitope spreading [18] and sub-
stantial tissue damage may have occurred before an
effective diagnosis has been made. Effective SIT for
AID will, therefore, require the induction of cells capable
of ‘bystander’ regulation or suppression at the earliest
stage of disease [19,20].
First attempts at SIT, in diseases such asmultiple sclerosis
(MS), were not successful [21–23]. Weiner and colleagues
extended these studies by testing the phenomenon of
mucosal tolerisation in various experimental models
[24]. This was universally effective and revealed that a
relatively low dose of antigen, delivered by the oral route,
would induce ‘bystander suppression’ whereby the admin-
istration of antigen A would induce cells capable of sup-
pressing responses to antigens B and C. Clinical trials
proved that oral tolerance induction is safe but not as
effective as expected from studies in animal models.
The administration of self-antigen via plasmid DNA is an
attractive approach since co-expression of cytokines andCurrent Opinion in Immunology 2010, 22:609–615immune modulators can be used to enhance mechanisms
of tolerance induction. Early examples of DNA vaccina-
tion in AID models produced conflicting results; disease
could be either suppressed [25] or enhanced [26,27],
depending on the disease model or antigen expressed.
Various approaches have been taken to enhance tolerance
induction. CpG motifs in plasmid DNA contribute to the
Th1 response; this is reduced by co-administration of an
oligonucleotide expressing GpG in place of CpG [28]. A
DNA vaccine encoding myelin basic protein, with CpG
motifs replaced by GpG, was recently tested in MS
patients [29]. Treatment with a 0.5 mg dose of DNA
resulted in the reduction of new lesions in the CNS,
coinciding with a decrease in the Th1 response to myelin
antigens. Co-expression of cytokines designed to reduce
the Th1 response to antigen enhanced the efficacy of
tolerogenic DNA vaccination in both EAE [30] and type I
diabetes (T1D)models [31]. An intriguing, novel approach
involves the introduction of the microRNA miR-142 into
the antigen-expressing vector [32]. The microRNA sup-
pressed antigen expression in professional APC and led to
the induction of antigen-specific FoxP3+ cells in the liver.
Expression of antigen in the liver generally enhances the
generation of induced FoxP3+ Treg cells and has proven
effective in models of uveitis and MS [33,34].
Although antigenic protein therapy has been successful in
pre-clinical models, the approach has not translated well
into the clinic. Nevertheless, there has been success in the
use of an alum-based islet-antigen vaccine. GAD-alum
treatment led to the preservation of residual insulin
secretion in patients with recent-onset T1D [35]. One
approach, designed to improve the safety of self-antigen
delivery in AID, involves the coupling of intact antigen to
APC using chemical fixatives [36]. This is based on the
concept that fixation promotes a tolerogenic response to
the APC. A systematic study of this approach, however,
revealed that efficacy is not dependent on the delivery of
antigen on autologous cells; in fact, cells may be replaced
with antigen-coated beads [37]. This implies that the fixed
cells themselves are not directly involved in tolerancewww.sciencedirect.com
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Table 2
Studies demonstrating the efficacy of self-antigenic peptide SIT in autoimmune diseases.
AID Treatment Patients Outcome Ref.
Rheumatoid Arthritis DNAJP1 peptide peroral,
25 mg/day over six months
160 Immune deviation from TNF-a to IL-10;
combination of peptide and
hydroxychloroquine most effective
[52]
Systemic Lupus
Erythematosus
Three s.c. doses of spliceosomal
peptide P140 at two-week intervals
20 Anti-dsDNA antibody levels
reduced in 200 mg group
[53]
T1D Three i.d. doses of proinsulin
peptide at monthly intervals
48 Increase of IL-10-secreting T cells in
patients receiving 10 mg dose
[54]
T1D DiaPep 277, hsp60 peptide,
range of doses around 1 mg
>300 IL-10 production in response to therapy
associated with preservation of C-peptide
[55,56]
Primary Progressive
MS/Secondary
Progressive MS
MBP8298, 500 mg i.v. every six months 32 Reduction in CSF anti-MBP.
Delay to progression in DR2/DR4 subgroup
[57]induction; rather, they carry intact antigen to tolerogenic
APC for processing andpresentation.Aphase I trial of fixed
autologous peripheral blood leukocytes coupled with a
cocktail of seven encephalitogenic myelin peptides is
underway in early relapsing-remitting MS patients [38].Figure 1
Self-regulatory properties of effector Th populations through chronic/repetitiv
and Th17 populations is well established. Recent evidence from viral-infecti
allergen-specific and autoantigen-specific peptide therapy trials, suggests t
and can serve as a self-limiting mechanism [43,44]. Shown are the potentia
switch from effector T (T eff) to IL-10-secreting regulatory populations. Note
evidence does suggest that IL-10 helps host survival during helminth infecti
remains unclear.
www.sciencedirect.comThe alternative to coupling antigen to APC is simply to
administer soluble peptide via a tolerogenic route. Much
has been learned about the nature of the peptide, dose,
route of delivery and timing. The peptide must mimic
the naturally processed antigen when bound to majore stimulation. Differentiation of naı¨ve CD4+ T cells into effector Th1, Th2
on and helminth-infection models, as well as numerous
hat upregulation of IL-10 occurs during chronic or repetitive stimulation
l cytokines/transcription factors/signalling molecules that mediate the
that Th2 cells produce IL-10 upon initial differentiation, and while
on [44], whether this is a general feature of well-differentiated Th2 cells
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tional modification of the peptide may be required
[40], and treatment must be initiated as soon as possible
following definite diagnosis (e.g., a single peptide could
suppress diabetes at an early stage of disease while
treatment of late stage disease required administration
of a combination of peptides [41]). One approach to
improving the safety and efficacy of peptide therapy
has included the development of recombinant MHC–
peptide complexes. Treatment with sIAg7–pGAD65
complexes effectively blocked the development of dia-
betes in the NOD mouse; suppression was dependent on
induction of islet-cell-specific IL-10-secreting CD4+ T
cells [42]. Similarly, treatment with a single recombinant
MHC–peptide complex could reverse EAE through
induction of IL-10-secreting regulatory cells [43]. Clinical
trials of peptide therapy have shown promising results in a
range of AID (Table 2) with various routes of adminis-
tration and dosing schedules under investigation. Impor-
tantly, as in many pre-clinical models, IL-10 is frequently
associated with effective peptide therapy.
The importance of antigen dose and IL-10
production for the success of antigen-SIT
IL-10 secretion is a common self-regulatory property for
the major CD4+ T helper subsets, with Th1, Th2, Th9
and Th17 cells all shown to secrete IL-10 in the face of
chronic exposure to antigen (reviewed in [44,45]). Both
allergen-SIT and autoantigen-SIT exploit this natural IL-Figure 2
Dosing strategy for antigen-SIT. Repeated administration of high-dose/affini
tolerance, but the first few treatments may induce acute and sometimes seve
does it induce robust tolerance. The low dose does, however, allow for the
associated with the higher dose.
Current Opinion in Immunology 2010, 22:609–61510-secreting phenotype of highly differentiated effector
cells with repeated exposure to high-dose antigen con-
verting effector T cells to IL-10-secreting regulatory
populations (Figure 1). The greatest hazard of high-dose
peptide-specific therapy, however, is a harmful immune
response due to the initial burst of cell activation with
subsequent proliferation and excessive cytokine release.
This became evident in trials of altered peptide ligand
(APL) therapy in MS. Treatment was terminated when it
became evident that an allergic response to the peptide
had been induced at the highest dose [46,47]. Impor-
tantly, this problem was not observed at lower doses of
peptide. We have recently shown, using peptide
analogues, that anergy, suppression and IL-10 secretion
are dose or affinity dependent, with lower signal strength
leading to anergy and higher signal strength driving IL-10
secretion and effective regulation of the inflammatory
immune response [48]. Combined with the body of
knowledge from allergen-SIT, these data suggest that
initiating treatment with lower doses and building to the
highest maintenance dose allows the full benefit of tol-
erance induction while also protecting the recipient from
harmful side effects. We propose, therefore, that for
antigen-SIT in both allergy and AID, a stepwise
approach, with dose escalation activating T cells through
increasing strength of signal to a higher maintenance
dose, will induce tolerogenic IL-10-secreting cells,
capable of suppressing the effector properties of their
initiating population (Figure 2).ty antigen has the potential to induce the highest level of anergy and
re side effects. Low-dose antigen does not carry a risk of side effects, nor
gradual increase of the dose without the adverse effects normally
www.sciencedirect.com
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property of highly stimulated cells, dependent on tissue-
specific environmental cues for its maintenance, while
others suggest that the IL-10 locus can be genetically
modified in terminal differentiation. Recent evidence has
shown that sustained high-dose TCR signalling and high
levels of IL-12 were required for the induction and
maintenance of IL-10 secretion in Th1 cells, through
sustained ERK1 and ERK2 MAP kinase phosphorylation
[49]. However, for Th2 cells, epigenetic modification of
chromatin at the IL-10 locus has been demonstrated
[50,51]. Thus, the mechanistic details of IL-10 regulation
in T cells and the crucial question of whether IL-10
secretion can be imprinted remain open.
Conclusion
This review has highlighted recent advances in specific
immunotherapy for allergic and autoimmune disease.
One overriding conclusion is that regulatory mechanisms
involving IL-10 are important for effective therapy. Our
belief is that basic research should focus on means to
target tolerogenic APC; to promote, for example through
the use of appropriate adjuvants, secretion of IL-10 from
both APC and T cells; and to investigate the mechanisms
of dose escalation tolerance. Future clinical trials should
focus on patient groups that are most likely to benefit
from the treatment, for examplemajor changes should not
be expected in advanced stages of disease [38]; no SIT
trial should be undertaken without detailed investigation
of immunological changes arising from the treatment; and
intervention should be undertaken as early after diagnosis
as possible. Finally, the dose of antigen required for SIT
is the most critical consideration; dose escalation should
allow for a safe increase in dose until an effective, tolero-
genic dose is achieved.
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